The in vitro activities of two investigational quinolones, sparfloxacin (previously designated AT 4140) and PD 127391, were determined for 30 strains each of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum and compared with those of ciprofloxacin, tetracycline, clindamycin, and erythromycin. Erythromycin was the most active compound against M. pneumoniae (maximum MIC, <0.008 ,ug/ml). PD 127391 (MICs, <0.008 to 0.031 ,ug/ml), sparfloxacin (MICs, <0.008 to 0.25 pg/ml), clindamycin (MICs, <0.008 to 0.5 ,g/ml), and tetracycline (MICs, 0.063 to 0.25 pg/ml) were superior to ciprofloxacin (MICs, 0.5 to 2 ,ug/ml). Sparfloxacin and PD 127391 were active against M. hominis (MICs, <0.008 to 0.031 pg/ml for each) at concentrations comparable to those of clindamycin (MICs, <0.008 to 0.063 ,g/ml) and at concentrations lower than those of ciprofloxacin (MICs, 0.125 to 0.5 pg/ml). As expected, M. hominis was resistant to erythromycin (MICs, 32 to .256 ,ug/ml). For U. urealyticum, PD 127391 (MICs, 0.031 to 0.5 ,ug/ml) and sparfloxacin (MICs, 0.063 to 1 ,ug/ml) were superior to erythromycin (MICs, 0.25 to 4 ,g/ml), ciprofloxacin (MICs, 0.5 to 8 ,ug/ml), and clindamycin (MICs, 0.25 to 64 ,g/ml. Both new quinolones were equally active against tetracyclinesusceptible as well as -resistant strains of M. hominis and U. urealyticum. The possible influence of medium components and/or pH on MICs was evaluated by testing a Staphylococcus aureus reference strain with each antibiotic in SP-4 broth and 10-B broth and comparing the results with published MICs for this strain. MICs determined in 10-B broth for erythromycin were affected most. This study shows that the activities of sparfloxacin and PD 127391 are similar to one another and comparable or superior to those of other drugs used to treat mycoplasmal infections. The MICs of both new quinolones were consistently 2 to several dilutions lower than those of ciprofloxacin for each species.
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Mycoplasma pneumoniae has long been recognized as a common pulmonary pathogen, especially in younger age groups, causing as much as 20% of pneumonia in the general population and up to 50% in military settings (3) . Most respiratory infections due to M. pneumoniae are self-limiting, but in some instances life-threatening disease may occur (3) . Although naturally occurring strains of M. pneumoniae resistant to erythromycin have not been described to date, the effectiveness of this drug may be limited in some cases because of dose-related nausea, vomiting, or diarrhea, justifying the need for alternative treatment modalities (9) . Knowledge of the antibiotic susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum is of increasing importance because of the recognition of these organisms as opportunistic pathogens in newborn infants (4-6, 42, 45) and other immunosuppressed persons (36) and as primary pathogens in sexually transmitted diseases such as nongonococcal urethritis (5) and pelvic inflammatory disease (5). Resistance to traditional drugs such as tetracycline, which has been widely used in treating mycoplasmal infections and other sexually transmitted diseases, is now recognized in both U. urealyticum and M. hominis to some extent (10, 13, 28, 35) . Increasing reports of P-lactamase-producing and tetracycline-resistant strains of Neisseria gonorrhoeae have further intensified the search for new agents to treat sexually transmitted infections (19) .
Fluoroquinolones represent a new class of broad-spectrum antimicrobial agents active against many gram-positive (unpublished data). Five isolates previously shown in our laboratory to be tetracycline resistant (MIC, . 16 ,ug/ml) (37) were included. The sources of the M. pneumoniae isolates tested have been described previously (8 Broth was observed for evidence of growth (color change) after overnight incubation and daily until the endpoint was first evident. The MIC was defined as the lowest concentration of antibiotic by which growth was inhibited when the positive control tube first showed a color change, usually after 16 to 20 h of incubation for U. urealyticum but sometimes longer for M. hominis and M. pneumoniae (4 days or more). All assays were repeated in duplicate on a different day to verify reproducibility.
Controls. A positive (growth) control consisting of organisms in broth, a negative (sterility) control consisting of uninoculated broth, and a drug control consisting of broth containing the highest concentration of drug were included for each mycoplasmal strain tested. The color-changing units of each strain per ml were determined for the inoculum actually used in the procedure by making 10-fold dilutions (0.1 ml of organism suspension per 0.9 ml of broth) to 10-8. This back titration of organisms was inoculated.
Mycoplasmal requirements for specialized enriched media, along with lower pHs for optimal cultivation and testing of ureaplasmas (31) , necessitate that considerable deviation be made from the acceptable procedures used for susceptibility testing of conventional bacteria. As a control for potential interactions between antibiotics, medium components, and pH which could potentially affect observed MICs, American Type Culture Collection bacterial reference strain Staphylococcus aureus ATCC 29213, with published MICs obtained in Mueller-Hinton broth for each of the drugs tested (37), was inoculated into microtiter plates containing 10-B broth, SP-4 broth, and appropriate dilutions of the six antibiotics for MIC determinations. These control procedures were repeated each time an assay was performed.
RESULTS
Susceptibilities of mycoplasmas to antibiotics. The broth microdilution susceptibility testing method has been shown in our laboratory to be an accurate, reproducible means for determining antibiotic susceptibilities of U. urealyticum (44) . In the present study, the assay was reproducible within +1 dilution for all MICs reported for both well-to-well testing and batch-to-batch testing. Table 1 shows the MICs obtained for six antibiotics tested against M. pneumoniae, M. hominis, and U. urealyticum.
Erythromycin was the most active antibiotic tested against M. pneumoniae, the MIC for all strains being <0.008 ,ug/ml. Tetracycline and clindamycin also showed favorable activities against all strains at slightly higher levels, with no MIC for any strain being >0.5 ,ug/ml. Sparfloxacin and PD 127391 were active against M. pneumoniae, with no MIC being >0.25 ,ug/ml. Each of these new quinolones was relatively more active than was ciprofloxacin (MICs, 0.5 to 2 ,g/ml).
The M. hominis strains tested in this study showed the predictable uniform resistance to erythromycin (MICs, 32 to >256 ,ug/ml) and susceptibility to clindamycin at low levels (MICs, <0.008 to 0.063 ,ug/ml). Sparfloxacin and PD 127391 showed comparable activities against all strains of M. hominis, the MICs being essentially equivalent to those of clindamycin. The MICs of sparfloxacin and PD 127391 were equal to or lower than those of tetracycline for every strain, the maximum MIC being 0.031 ,ug/ml. No difference in the activities of sparfloxacin and PD 127391 against tetracyclineresistant and tetracycline-susceptible M. hominis strains was observed. Ciprofloxacin was slightly less active against M. hominis (MICs, 0.125 to 0.5 ,ug/ml) than were the two newer quinolones.
The U. urealyticum strains were inhibited by erythromycin at MICs ranging from 0.25 to 4 ,ug/ml, with MICs for 50% and PD 127391 MICs were not affected when the assay was performed with 10-B broth (pH 6.0).
DISCUSSION
It can be generalized that the quinolones evaluated to date, as a group, show moderate activity against mycoplasmas (12). However, results and interpretations of the numerous publications dealing with in vitro potencies of quinolones against mycoplasmas have varied considerably (1, 2, 7, 8, 11, 15, 17-21, 25-27, 33, 39, 41, 46) . The reasons for such disparities, other than extremely small numbers of strains tested in some studies, are likely related to differences in technique, inoculum size, incubation conditions, pH, media, or endpoints measured. Until universally applied standards are in place for performing susceptibility tests on mycoplasmas, further discrepancies can be expected.
Studies comparing the activities of various antibiotics with that of erythromycin against M. pneumoniae have shown that the macrolide consistently has the lowest MICs, often by several dilutions (8, 18, 24, 25, 41, 46) . Quinolones may have favorable MICs, and some may perform better than others (14, 18, 19, (24) (25) (26) . Nakamura et al. (24) found sparfloxacin to be highly active (M'C50, 0.1 ,ug/ml) against M. pneumoniae, its MICs being lower than those of ciprofloxacin, ofloxacin, enoxacin, norfloxacin, and minocycline. Kenny and Cartwright (18) found WIN 57273 (MICs, 0.125 to 0.25 p.g/ml) and sparfloxacin (MICs, 0.25 to 0.5 ,ug/ml) to be more potent than tetracycline, ofloxacin, lomefloxacin, and fleroxacin. Sparfloxacin and WIN 57273 were the only quinolones tested with MICs of <1 ,ug/ml. These results are generally in agreement with the findings of the present study.
M. hominis may be inhibited by theoretically attainable concentrations of ciprofloxacin according to a number of studies (14, 17, 19, 26, 27, 39, 46) . MICs for other quinolones have also been reported (17, 19, 20, 26, 27, 33, 39, 41, 46 (1, 2, 7, 15, 17, 19, 26, 27, 33, 39, 46) .
The possibility that the specialized media and conditions necessary for optimal cultivation and susceptibility testing of mycoplasmas may exert some effect on the activity and/or stability of various antimicrobial agents cannot be discounted, as our results indicate. Microbial susceptibility VOL. 35, 1991 on September 29, 2017 by guest http://aac.asm.org/ Downloaded from tests are best performed near the physiologic pH in welldefined media for standardization purposes (22, 37, 38) . Susceptibility testing of ureaplasmas in broth must be carried out at pH 6 to 6.5 because of the growth requirements of the organism and the indicator reaction necessary for the interpretation of the endpoint (31, 32) . Erythromycin MICs may be several dilutions higher at pH 6.0 to 6.5 than at the physiologic pH, such that actual activity in vivo may be greater than that indicated by assays performed at a lower pH (22, 38, 41) . The reason for the diminished activity of erythromycin in vitro is thought to be due to its greater degree of ionization at a lower pH and the fact that the un-ionized form may be more directly responsible for antimicrobial activity (38) . The influence of pH on ureaplasmal growth and interpretation of erythromycin susceptibility is the root of considerable controversy surrounding the utility of this antibiotic in treating infections caused by this organism. It is most likely that pH, rather than medium components in 10-B broth, is primarily responsible for the observed effects on erythromycin MICs, since the MICs of erythromycin for M. pneumoniae in SP-4 broth (pH 7.5), similar in many respects to 10-B broth, were consistently very low (<0.008 ,g/ml). Erythromycin MICs for S. aureus ATCC 29213 in SP-4 broth were also within the acceptable range established for Mueller-Hinton broth (37) . We believe that the MICs obtained in this study for erythromycin against U. urealyticum are meaningful, because of the relatively narrow range observed (0.25 to 4 ,g/ml) and the apparent scarcity of high-level resistance, which would likely be detected even under the present assay conditions. Prospective studies of patients with ureaplasmal infections treated with erythromycin and for whom both in vitro MICs and in vivo microbiological efficacy are determined will be needed to further clarify this complex relationship. Lincosamide MICs may also be elevated at an acidic pH, while tetracyclines may be more active (38) . The (7, 23) . Sparfloxacin is well absorbed orally, has a relatively long half-life in plasma, and has good tissue distribution (29) . Preliminary studies have shown that the toxicity of sparfloxacin is low enough to allow the initiation of clinical trials, which will be required to evaluate its clinical utility against pathogenic mycoplasmas (16) . 
